Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Claudia Marchetti; I. Palaia; F. De Felice; A. Musella; C. Donfracesco; L. Vertechy; A. Romito; I. Piacenti; D. Musio; L. Muzii; V. Tombolini; P. Benedetti Panici

doi:10.1016/j.ctrv.2015.10.011

Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Claudia Marchetti, I. Palaia, F. De Felice, A. Musella, C. Donfracesco, L. Vertechy, A. Romito, I. Piacenti, D. Musio, L. Muzii, V. Tombolini, P. Benedetti Panici

University of Rome La Sapienza

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

Lingua originale	English
pagine (da-a)	41-46
Numero di pagine	6
Rivista	Cancer Treatment Reviews
Volume	42
DOI	https://doi.org/10.1016/j.ctrv.2015.10.011
Stato di pubblicazione	Pubblicato - 2016

Keywords

Gynecologic
Ovarian cancer
Platinum resistant
Recurrence
Tyrosine-kinases inhibitors

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.ctrv.2015.10.011

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{d7ebb6afea494c119c0c61ad16953abe,

title = "Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients",

abstract = "For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.",

keywords = "Gynecologic, Ovarian cancer, Platinum resistant, Recurrence, Tyrosine-kinases inhibitors, Gynecologic, Ovarian cancer, Platinum resistant, Recurrence, Tyrosine-kinases inhibitors",

author = "Claudia Marchetti and I. Palaia and {De Felice}, F. and A. Musella and C. Donfracesco and L. Vertechy and A. Romito and I. Piacenti and D. Musio and L. Muzii and V. Tombolini and {Benedetti Panici}, P.",

year = "2016",

doi = "10.1016/j.ctrv.2015.10.011",

language = "English",

volume = "42",

pages = "41--46",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

AU - Marchetti, Claudia

AU - Palaia, I.

AU - De Felice, F.

AU - Musella, A.

AU - Donfracesco, C.

AU - Vertechy, L.

AU - Romito, A.

AU - Piacenti, I.

AU - Musio, D.

AU - Muzii, L.

AU - Tombolini, V.

AU - Benedetti Panici, P.

PY - 2016

Y1 - 2016

N2 - For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

AB - For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.

KW - Gynecologic

KW - Ovarian cancer

KW - Platinum resistant

KW - Recurrence

KW - Tyrosine-kinases inhibitors

KW - Gynecologic

KW - Ovarian cancer

KW - Platinum resistant

KW - Recurrence

KW - Tyrosine-kinases inhibitors

UR - http://hdl.handle.net/10807/205128

U2 - 10.1016/j.ctrv.2015.10.011

DO - 10.1016/j.ctrv.2015.10.011

M3 - Article

SN - 0305-7372

VL - 42

SP - 41

EP - 46

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -

Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo